{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T07:54:08Z","timestamp":1790409248532,"version":"4.1.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T00:00:00Z","timestamp":1667520000000},"content-version":"vor","delay-in-days":1525,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1111\/jth.14207","type":"journal-article","created":{"date-parts":[[2018,6,16]],"date-time":"2018-06-16T05:44:21Z","timestamp":1529127861000},"page":"1722-1731","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":78,"title":["A first\u2010in\u2010human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of PF\u201006741086, an anti\u2010tissue factor pathway inhibitor mAb, in healthy volunteers"],"prefix":"10.1016","volume":"16","author":[{"given":"M.","family":"Cardinal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Kantaridis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.D.","family":"Pittman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.E.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Arkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/jth.14207_bb0010","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1182\/blood-2017-08-742312","article-title":"Novel approaches to hemophilia therapy: successes and challenges","volume":"130","author":"Arruda","year":"2017","journal-title":"Blood"},{"key":"10.1111\/jth.14207_bb0015","first-page":"262","article-title":"Tissue factor pathway inhibitor: structure\u2013function","volume":"7","author":"Broze","year":"2014","journal-title":"Front Biosci"},{"key":"10.1111\/jth.14207_bb0020","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1182\/blood-2013-11-512764","article-title":"Biology of tissue factor pathway inhibitor","volume":"123","author":"Wood","year":"2014","journal-title":"Blood"},{"key":"10.1111\/jth.14207_bb0025","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/jth.12188","article-title":"Comparison of the inhibitory activities of human tissue factor pathway inhibitor (TFPI)\u03b1 and TFPI\u03b2","volume":"11","author":"Maroney","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14207_bb0030","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1055\/s-0038-1646989","article-title":"Modifications of extrinsic pathway inhibitor (EPI) and factor Xa that affect their ability to interact and to inhibit factor VIIa\/tissue factor: evidence for a two\u2010step model of inhibition","volume":"60","author":"Warn\u2010Cramer","year":"1988","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.14207_bb0035","doi-asserted-by":"crossref","first-page":"17838","DOI":"10.1073\/pnas.1310444110","article-title":"Tissue factor pathway inhibitor\u2010alpha inhibits prothrombinase during the initiation of blood coagulation","volume":"110","author":"Wood","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"issue":"Suppl 4","key":"10.1111\/jth.14207_bb0040","first-page":"79","article-title":"PF\u201006741086, a monoclonal antibody with tissue factor pathway inhibitor (TFPI) neutralizing activity, improves coagulation parameters in global hemostatic assays in hemophilic whole blood and plasma","volume":"22","author":"Hett","year":"2016","journal-title":"Haemophilia"},{"issue":"Suppl 1","key":"10.1111\/jth.14207_bb0045","first-page":"757","article-title":"Efficacy of anti\u2010TFPI antibody PF\u201006741086 compared to rFactor VIIa in mouse hemophilia A bleeding models","volume":"22","author":"Jasuja","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1111\/jth.14207_bb0050","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1160\/TH04-10-0706","article-title":"Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B","volume":"93","author":"Dargaud","year":"2005","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.14207_bb0055","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1111\/j.1538-7836.2007.02663.x","article-title":"Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors","volume":"5","author":"Konkle","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14207_bb0060","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/jth.12864","article-title":"Safety and pharmacokinetics of anti\u2010TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial","volume":"13","author":"Chowdary","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14207_bb0065","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/hae.13260","article-title":"Concizumab, an anti\u2010tissue factor pathway inhibitor antibody, induces increased thrombin generation in plasma from haemophilia patients and healthy subjects measured by the thrombin generation assay","volume":"23","author":"Waters","year":"2017","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14207_bb0070","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1208\/s12248-017-0086-4","article-title":"Mechanistic modeling of the pharmacodynamic and pharmacokinetic relationship of tissue factor pathway inhibitor\u2010neutralizing antibody (BAY 1093884) in cynomolgus monkeys","volume":"19","author":"Gu","year":"2017","journal-title":"AAPS J"},{"key":"10.1111\/jth.14207_bb0075","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/j.xphs.2018.03.010","article-title":"Translational PK\/PD characterization and TMDD modeling of an anti\u2010TFPI antibody, PF\u201006741086","volume":"107","author":"Parng","year":"2018","journal-title":"J Pharm Sci"},{"issue":"Suppl. 2","key":"10.1111\/jth.14207_bb0080","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/S0049-3848(16)30359-0","article-title":"Targeting TFPI for hemophilia treatment","volume":"141","author":"Peterson","year":"2016","journal-title":"Thromb Res"},{"key":"10.1111\/jth.14207_bb0085","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1182\/blood.V128.22.2566.2566","article-title":"An antibody to tissue factor pathway inhibitor (PF\u201006741086) in combination with recombinant factor VIIa increases hemostasis in hemophilia plasma without excessive thrombin generation","volume":"128","author":"Rakhe","year":"2016","journal-title":"Blood"},{"key":"10.1111\/jth.14207_bb0090","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1111\/jth.12201","article-title":"Aptamer BAX 499 mediates inhibition of tissue factor pathway inhibitor via interaction with multiple domains of the protein","volume":"11","author":"Waters","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14207_bb0095","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1182\/blood.V120.21.2207.2207","article-title":"Effect of increased tissue factor pathway inhibitor (TFPI) levels on factor Xa inhibition and global hemostasis in the presence of TFPI\u2010antagonistic aptamer BAX 499","volume":"120","author":"Dockal","year":"2012","journal-title":"Blood"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.14207","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622023492?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622023492?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jth.14207\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:21:00Z","timestamp":1761535260000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622023492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S1538783622023492"],"URL":"https:\/\/doi.org\/10.1111\/jth.14207","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A first\u2010in\u2010human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of PF\u201006741086, an anti\u2010tissue factor pathway inhibitor mAb, in healthy volunteers","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.14207","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2018 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}